Trial reportBMC primary care2026
Increasing colorectal cancer screening among Alaska Native peoples living in remote areas of Alaska: a multitarget stool DNA cluster randomized controlled trial.
Trial report in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04336397 (Randomized Controlled Trial of the Stool DNA Test to Improve Colorectal Cancer Screening Among Alaska Native People), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial of the Stool DNA Test to Improve Colorectal Cancer Screening Among Alaska Native People
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIncreased colorectal cancer (CRC) screening is needed to address high Alaska Native (AN) CRC rates. The study objective was to evaluate high-intensity vs. medium-intensity patient outreach using multi-target stool DNA (mt-sDNA) or colonoscopy.
methodsA community-level, cluster-randomized clinical trial (April 29, 2021, through September 15, 2024) in 46 rural/remote Alaska communities. Participants were asymptomatic AN adults aged 45-75 with no family or personal history of CRC who were due for screening. High-intensity: Up to six patient navigator telephone calls with follow-up mailer. Medium-intensity: Mailed letter with one follow-up call. Usual care: Standard of care clinical visits. The primary outcome was screening completion within 12 months. Secondary outcomes included test preference, abnormal mt-sDNA follow-up colonoscopy, and colonoscopy outcomes.
resultsA total of 2029 AN people (mean [SD] age, 56 [8.4] years; 816 women [40%]) were randomized including 587 to usual care, 696 to medium-intensity, and 746 to the high-intensity arm. Both men and women were significantly more likely to request mt-sDNA (70%) over colonoscopy (30%, p < 0.01), with participants ≥ 65 years old most likely to request mt-sDNA. Screening completion within 12 months among the total population was significantly higher in the medium-intensity (24%) and high-intensity arms (28%) compared with usual care (6%) (p<0.01). Compared to usual care, CRC screening odds were higher with high-intensity (odds ratio [OR], 5.90; 95% CI, 3.86-9.04) and medium-intensity intervention (OR, 4.87; 95% CI, 3.18-7.46). Among those who agreed to screen, completion was similar in both intervention arms. Screening completion was 16% higher among high-intensity vs. medium-intensity participants (OR, 1.25; 95% CI, 0.91-1.71, p=0.19). Of the total eligible population, 254/2029 people (12.5%) had valid mt-sDNA tests and 278/2029 (13.7%) had complete colonoscopies. CRC/advanced neoplasia was found in over 25% of initial screening colonoscopies and 59% of colonoscopies performed after abnormal mt-sDNA.
conclusionsBoth a medium- and a high-intensity intervention were significantly more effective at increasing screening initiation and completion rates compared with usual care in rural/remote Alaskan communities. Participants significantly preferred mt-sDNA for screening. These findings highlight the clinical utility of focused outreach strategies in primary care settings and support the use of mt-sDNA as a viable alternative to colonoscopy in geographically isolated populations.
trial registrationThe study is registered with the Clinical Trials Registry (Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People, NCT04336397, https//www.cancer.gov/research/participate/clinicaltrialssearch/v? id=NCI202108691, registration date 04/03/2020) and was designed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.